These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15353981)

  • 1. Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions.
    Yerly S; Günthard HF; Fagard C; Joos B; Perneger TV; Hirschel B; Perrin L;
    AIDS; 2004 Sep; 18(14):1951-3. PubMed ID: 15353981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual viraemia in subjects with chronic HIV infection and viral load < 50 copies/ml: the impact of highly active antiretroviral therapy.
    Palmisano L; Giuliano M; Nicastri E; Pirillo MF; Andreotti M; Galluzzo CM; Bucciardini R; Fragola V; Andreoni M; Vella S
    AIDS; 2005 Nov; 19(16):1843-7. PubMed ID: 16227792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virological characterization of patients treated early is able to control HIV-1 replication after multiple cycles of structured therapy interruption.
    Rozera G; Abbate I; D'Offizi G; Corpolongo A; Narciso P; Vlassi C; Martini F; Calcaterra S; Capobianchi MR
    J Med Virol; 2007 Aug; 79(8):1047-54. PubMed ID: 17597482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-resistance mutations number and K70R or T215Y/F substitutions predict treatment resumption during guided treatment interruptions.
    Darwich L; Esteve A; Ruiz L; Paredes R; Bellido R; Cabrera C; Romeu J; Bofill M; Clotet B; Martinez-Picado J
    AIDS Res Hum Retroviruses; 2008 May; 24(5):725-32. PubMed ID: 18462084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia.
    Seclén E; Del Mar González M; De Mendoza C; Soriano V; Poveda E
    J Antimicrob Chemother; 2010 Jul; 65(7):1493-6. PubMed ID: 20488982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.
    Mohey R; Jørgensen LB; Møller BK; Black FT; Kjems J; Obel N
    J Clin Virol; 2005 Dec; 34(4):257-67. PubMed ID: 16286049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-level viraemia on HAART: significance and management.
    Doyle T; Geretti AM
    Curr Opin Infect Dis; 2012 Feb; 25(1):17-25. PubMed ID: 22156900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 DNA and RNA kinetics in primary HIV infection.
    Lillo F; Grasso M; Lodini S; Capiluppi B; Lazzarin A; Tambussi G
    J Biol Regul Homeost Agents; 2002; 16(1):49-52. PubMed ID: 12003174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial).
    Stellbrink HJ; van Lunzen J; Westby M; O'Sullivan E; Schneider C; Adam A; Weitner L; Kuhlmann B; Hoffmann C; Fenske S; Aries PS; Degen O; Eggers C; Petersen H; Haag F; Horst HA; Dalhoff K; Möcklinghoff C; Cammack N; Tenner-Racz K; Racz P
    AIDS; 2002 Jul; 16(11):1479-87. PubMed ID: 12131185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution.
    Lambotte O; Chaix ML; Gubler B; Nasreddine N; Wallon C; Goujard C; Rouzioux C; Taoufik Y; Delfraissy JF
    AIDS; 2004 May; 18(8):1147-58. PubMed ID: 15166530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular proviral HIV-DNA decline and viral isolation in naïve subjects with <5000 copies/ml of HIV-RNA and >500 x 10(6)/l CD4 cells treated with highly active antiretroviral therapy.
    Andreoni M; Parisi SG; Sarmati L; Nicastri E; Ercoli L; Mancino G; Sotgiu G; Mannazzu M; Trevenzoli M; Tridente G; Concia E; Aceti A
    AIDS; 2000 Jan; 14(1):23-9. PubMed ID: 10714564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alleles of the gene encoding IL-1alpha may predict control of plasma viraemia in HIV-1 patients on highly active antiretroviral therapy.
    Price P; James I; Fernandez S; French MA
    AIDS; 2004 Jul; 18(11):1495-501. PubMed ID: 15238767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV drug resistance mutations in proviral DNA from a community treatment program.
    Derache A; Shin HS; Balamane M; White E; Israelski D; Klausner JD; Freeman AH; Katzenstein D
    PLoS One; 2015; 10(1):e0117430. PubMed ID: 25635815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modifications of residual viraemia in human immunodeficiency virus-1-infected subjects undergoing repeated highly active antiretroviral therapy interruptions.
    Palmisano L; Giuliano M; Bucciardini R; Andreotti M; Fragola V; Pirillo MF; Weimer LE; Mancini MG; Vella S
    J Med Microbiol; 2009 Jan; 58(Pt 1):121-124. PubMed ID: 19074663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA.
    Gianella S; von Wyl V; Fischer M; Niederoest B; Battegay M; Bernasconi E; Cavassini M; Rauch A; Hirschel B; Vernazza P; Weber R; Joos B; Günthard HF;
    Antivir Ther; 2011; 16(4):535-45. PubMed ID: 21685541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of pre-therapy viral load on virological response to modern first-line HAART.
    Santoro MM; Armenia D; Alteri C; Flandre P; Calcagno A; Santoro M; Gori C; Fabeni L; Bellagamba R; Borghi V; Forbici F; Latini A; Palamara G; Libertone R; Tozzi V; Boumis E; Tommasi C; Pinnetti C; Ammassari A; Nicastri E; Buonomini A; Svicher V; Andreoni M; Narciso P; Mussini C; Antinori A; Ceccherini-Silberstein F; Di Perri G; Perno CF
    Antivir Ther; 2013; 18(7):867-76. PubMed ID: 23343501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy.
    Ngo-Giang-Huong N; Deveau C; Da Silva I; Pellegrin I; Venet A; Harzic M; Sinet M; Delfraissy JF; Meyer L; Goujard C; Rouzioux C;
    AIDS; 2001 Apr; 15(6):665-73. PubMed ID: 11371680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.